AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data
The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.
You may also be interested in...
AstraZeneca’s Enthusiasm For Vaccines On The Wane
As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.
Pfizer’s Talzenna Takes On Top Dog Lynparza In Prostate Cancer
Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.
Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC
A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.